FDA Reviews Trexima for Treatment of Migraines

DECEMBER 01, 2005
Susan Farley

GlaxoSmithKline and POZEN Inc announced that the drug Trexima will be reviewed by the FDA for the acute treatment of migraine headaches. The companies have proposed Trexima as the brand name for their combination of sumatriptan succinate (Imitrex) and naproxen sodium (Aleve, for example) in a single-tablet form. Pending approval by the FDA, Trexima could be available to the public by the second half of 2006.

Ms. Farley is a freelance medical writer based in Wakefield, RI.




SHARE THIS SHARE THIS
0
 

The Oncology Care Pharmacist in Health-System Pharmacy 
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.


 

Pharmacy Times Strategic Alliance
 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.